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Does Restricted Distribution Limit
Access and Coverage of Yellow Fever
Vaccine in the United States?
Yellow fever, the original viral hemorrhagic
fever, is a mosquito-borne infection character-
ized by hepatic, renal, and myocardial injury,
bleeding, and a high case-fatality rate. The
disease occurs in tropical South America and
sub-Saharan Africa. Maintained by zoonotic
transmission between sylvan mosquitoes and
nonhuman primates, the virus cannot be
eradicated, and prevention of human infection
requires high vaccination coverage. Recently the
incidence of yellow fever has increased
dramatically (1), with 23,543 cases and 6,421
deaths officially reported to the World Health
Organization (WHO) between 1985 and 1996.
The true incidence is believed to far exceed the
reported incidence. Yellow fever remains a public
health problem because of failure to implement
effective immunization, particularly in Africa.
The recent upsurge in yellow fever activity
has been associated with an increased risk for
infection among unimmunized travelers. In
1996, two tourists infected in the Amazon region
of Brazil died after returning to the United
States (2) and Switzerland (3). Fatal and other
cases in tourists were also reported in previous
years (4-8). Other cases were likely missed,
misdiagnosed as viral hepatitis, treated
abroad, or not reported.
Since viremic humans are the source of
infection for the epidemic mosquito vector Aedes
aegypti, unimmunized travelers may import
yellow fever to Ae. aegypti-infested regions,
including the United States, West Indies,
Central America, Mediterranean region, and
Asia. The expansion of international travel,
including adventure travel to remote and
tropical areas, has increased exposure to yellow
fever and other exotic infections (9). Each year
eight to nine million tourists arrive in yellow
fever-endemic countries in South America and
Africa (10,11); the number of tourists visiting
regions within countries in which yellow fever
transmission occurs is unknown but probably
exceeds three million. In the United States,
150,000 to 300,000 civilian travelers are
immunized annually (12)likely only a fraction
of the population requiring the vaccine.
However, few data exist on vaccine coverage in
travelers to yellow feverendemic regions. One
survey in the United States found that 30% of
travelers to developing countries between 1980
and 1986 received yellow fever vaccine (13).
Yellow fever vaccine coverage of European
travelers varied from 0% to 90% (14,15).
WHO and the Centers for Disease Control
and Prevention strongly recommend vaccination
for travel outside urban areas in the yellow
feverendemic zone (16,17). Yellow fever 17D, a
live, attenuated, vaccine developed in 1936, has
been used in more than 300 million persons and
has a remarkable record of safety, tolerance, and
efficacy (18). Immunity develops rapidly after a
single dose and is extraordinarily durable,
probably lifelong. Yellow fever vaccine can be
administered simultaneously with most other
vaccines or immune serum globulin recom-
mended for international travel. Cost of the
vaccine is approximately $48 for a single-dose
vial in the United States. Thus, the attributes of
the vaccine itself do not constitute a barrier to
the immunization of travelers.
Yellow fever is the only human vaccine
subjected to regulations regarding distribution.
The International Health Regulations (19)
require that yellow fever vaccine be given in
approved vaccinating centers, listed in a 1991
WHO publication (20) and updated in the WHO
Weekly Epidemiological Record. The restriction
was instituted to ensure that the relatively
thermolabile vaccine is properly stored and
delivered within the specified time after
reconstitution and that a signed vaccination
certificate is properly completed (specifying the
date of immunization and the vaccine lot) and
bears an official stamp. Only authorized medical
facilities may order vaccine directly from the
manufacturer, and the vaccine is not available
through the normal distribution channels for
drugs and biologic products.
In the United States, registration and
approval of yellow fever vaccinating centers has
been delegated by the U.S. Public Health Service
to the state health departments. With the
expansion of international travel in recent years
and a growing number of travel clinics, this
system has become unwieldy, and its listing of
active centers is inaccurate.
The Problem, the Risks, a Solution
The United States currently has 800 to 1,000
yellow fever vaccinating centers. Many are
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in travel medicine. However, most travelers first
seek pretravel medical advice from their
primary-care providers. Immunizations and
prophylactic measures against many travel-
related threats, such as hepatitis A, typhoid,
diphtheria, and measles, are commonly given by
primary-care providers; even more specialized
travel vaccines, such as rabies, meningococcal,
and Japanese encephalitis vaccines, are readily
available to general practitioners. Specific
recommendations for the use of travel vaccines
are in publications (19,20) and on the Internet.
Yellow fever is the only travel vaccine for
which the primary-care physician must refer the
patient to another provider. Compliance with
recommendations for immmunization is affected
by multiple factors (21), including inconvenient
access to a vaccine. A Tennessee resident who
died of yellow fever in 1996 was not vaccinated
before going to Brazil because the official
vaccinating center nearest his home was 25
miles away (2). In contrast, he had received other
medical advice, hepatitis A vaccine, and a
prescription for malaria chemoprophylaxis from
his primary-care physician. Since requests for
yellow fever vaccine may be few, most physicians
do not initiate the complicated process of
obtaining authorization as a designated vacci-
nating center. In the United Kingdom, however,
where general practitioners have become
proactive in providing travel advice to their
patients, the number of physicians who obtained
yellow fever vaccinating center status rose from
181 to 1,231 between 1990 and 1992 (22).
The disadvantages of general practitioners
engaging in travel medicine, including the
immunization of travelers against exotic infec-
tions and prescription of malaria chemoprophy-
laxis, have been examined in several studies,
which suggest that improvements are needed in
the quality of advice provided to patients (23,24).
Among Swiss and German general practitioners,
only 11% and 1%, respectively, provided correct
recommendations to travelers to Thailand and
Kenya regarding malaria prophylaxis and
vaccinations (25). County health departments in
the United States responsible for yellow fever
vaccination have limited expertise in travel
medicine. While extending the distribution of
yellow fever vaccine to primary health-care
providers would increase access to the vaccine
and improve coverage, additional steps are
required to improve the quality of medical advice
by giving practitioners accurate and simple
information to guide use of the vaccine. Public
health department nurses and inspectors in
Ontario, Canada, provided correct recommenda-
tions for yellow fever vaccination 96% of the time
(26), reflecting the value of education in this field.
Travelers requiring yellow fever and other
live virus vaccines face special problems. The
current recommendation is for either simulta-
neous administration or separation of the
vaccines by 4 weeks to avoid potential
interference (16). Compliance with this recom-
mendation is difficult, and the recommendation
is probably ignored when the patient receives
some vaccines from the primary-care physician
and yellow fever vaccine at a designated center.
The recommendation provides a further incen-
tive for a single health professional to administer
a schedule of immunizations appropriate for the
individual traveler.
We sampled 15 states, which contained a
very high proportion of the U.S. population (44%)
and were representative with respect to
geography, urban-rural distribution, and race.
Although we could not estimate whether these
states were different from the United States as a
whole with respect to international travel, we
believe that it is reasonable to extrapolate the
findings with respect to access to vaccinating
centers to the general population. We found that
the current system of designated yellow fever
vaccinating centers in the United States
provides reasonable access to approximately 95%
of the population, where reasonable access is
defined as residence within a 25-mile radius of
the vaccinating center (Table). Although this
would appear sufficient, in fact there may be
substantial obstaclesfrom the perspective of
the patientto utilization of centers within
geographic proximity (the 25-mile catchment
area), including extra costs, inconvenience of
access to centers within congested urban areas,
and unfamiliarity with the provider. Approxi-
mately 5% to 6% of the total U.S. population (12
to 14 million) resides in rural areas that are
relatively inaccessible to vaccinating centers
(Table).  In some states, such as Montana,
Wyoming, Oklahoma, and Vermont, approxi-
mately 25% of the population resides outside 25-
mile catchment areas, and very long distances
must be traveled to reach a center (Figure), with
the result that only highly motivated patients
are vaccinated. Although it is possible that urban700 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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residents with better access to vaccinating centers
are more likely to internationally travel than rural
residents, our analysis clearly demonstrated that
restricted access to yellow fever vaccine by
populations in rural or sparsely populated areas.
In the past, a principal concern underlying
the restricted distribution of yellow fever vaccine
was the thermolability of the vaccine and the
need to ensure its proper storage and handling.
However, other vaccines in wide use have similar
or even more stringent storage requirements.
Tetanus toxoid must be stored refrigerated away
from the freezer compartment, measles-mumps-
rubella must be stored refrigerated and
protected from light, and varicella vaccine must
be stored frozen. Yellow fever vaccine manufac-
turers now include stabilizers in the product that
render the lyophilized vaccines quite resistant to
degradation (27-29). Yellow fever vaccine is
stored in the refrigerator at the point of use, as
are most other vaccines. Yellow fever vaccine is
discarded 1 hour after reconstitution; in
contrast, varicella vaccine must be discarded
within 30 minutes. Thus, the storage and
handling of yellow fever vaccine do not pose
special difficulties.
The International Health Regulations,
adopted nearly 30 years ago (19), require a valid
certificate of vaccination only for yellow fever
(17,19). This regulation recognizes the risk for
importation and spread of yellow fever across
international boundaries by viremic travelers.
However, enforcement is problematic and lax.
For example, in the Calcutta airport, closure of
the health inspection desk in 1986 virtually
eliminated verification of vaccination status of
disembarking passengers (30). A number of
yellow feverreceptive (Ae. aegypti-infested)
countries, including the United States, do not
require vaccination certificates (16,17), and
many countries require but do not enforce the
inspection of certificates. The United States
abandoned inspection of vaccination certificates
(because of the high cost and questionable public
health value of yellow fever quarantine
regulations) in favor of a system of surveillance
and optimization of health information to the
Table. Populations (1990 censusa) inside and outside 25-
mile radius ‘catchment areas’ of intrastate authorized yel-
low fever vaccinating centers
Population x103
Inside Outside
catchment catchment
Region State Total area (%) area (%)
East New York   17,991 17,679 (98.3)    312  (1 .7)
Massachu-    6,016   5,965 (99.2)      51   (0.8)
  setts
Connec-     3,287   3,287  (100)        0      (0)
  ticut
Vermont        563      418 (74.2)    145 (25.8)
South Florida   12,938 12,410 (95.9)    528   (4.1)
Louisiana     4,220   3,767 (89.3)    453 (10.7)
Cen- Illinois   11,431 10,125 (88.6) 1,306 (11.4)
  tral Wisconsin     4,892   4,331 (88.5)    561 (11.5)
Nebraska     1,578   1,293 (81.9)    285 (18.1)
Oklahoma    3,146   2,317 (73.6)    829 (26.4)
Moun- Montana        799      595 (74.5)    204 (25.5)
  tain Wyoming        454      350 (77.1)    104 (22.9)
Pacific California   29,758 29,138 (97.9)    620   (2.1)
Oregon     2,842   2,676 (94.2)    166   (5.8)
Hawaii     1,108      983 (88.7)    125 (11.3)
15 states 101,023 95,334 (94.4) 5,689   (5.6)
aU.S. Bureau of the Census, 1990 Decennial Census.
Figure. Location of yellow fever vaccinating centers in
three western states. The circles indicate the area
within a 25-mile radius from each center (catchment
areas). Only names of selected locations are shown.701 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
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traveling public. The difficulty in controlling
yellow fever vaccination through designated
centers and the lack of a clear justification on the
basis of thermostability of the vaccine led a WHO
working group on revisions to the International
Health Regulations to recommend reconsidera-
tion of designation procedures of vaccination
centers (31). We think the link between the
requirement for certification of yellow fever
vaccination imposed by some national health
authorities and the distribution of vaccine
through designated centers should be the focus
of future discussions between parties to the
International Health Regulations. Certification
of vaccination could be provided by any licensed
physician, as was the case for smallpox and
cholera vaccines at the time that these were
required for international travel. The blank
certificate (available from the Government
Printing Office) could, for example, be shipped
together with the vaccine from the manufac-
turer or distributor to the physician. A change
would be required in the International Health
Regulations to allow validation of the
certificate by physician signature alone
without application of the uniform stamp
currently used on the certificate.
The risk of acquiring yellow fever during
travel is related to the level of virus transmission
at the time and in the location visited. During
yellow fever epidemics, the risk to an
unimmunized person is very high, even during a
short visit to an endemic-disease area. In recent
outbreaks affecting indigenous populations in
West Africa, the incidence of infection during the
3-month epidemic period was 20% to 30% (32,33).
The risk of developing severe disease with
jaundice if infected has been estimated at 1:3.8 to
1:7.4 and the risk of dying if ill with jaundice is
20% to 60% (18). In areas where the indigenous
population is protected by vaccination, yellow
fever virus may circulate silently between
monkeys and mosquitoes without any reported
human cases as a guide to risk. Moreover, the
southern United States is infested with Ae.
aegypti, and importation of yellow fever poses a
considerable threat (34,35). The potential for
importation by persons infected with yellow
fever has increased with the establishment of
direct links between the United States and
disease-endemic areas, such as Manaus, Brazil,
and Iquitos, Peru (9). These factors provide a
strong rationale for immunizing all persons who
visit disease-endemic zones.
The current system of designated yellow
fever vaccinating centers and relative inaccessi-
bility to yellow fever vaccine are impediments to
full vaccination coverage of travelers. Extension
of vaccinating privileges to primary-care
providers, together with clear and concise
information regarding recommendations for use
of the vaccine, may improve protection of
travelers at risk and enhance the barrier to
importation of the disease.
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